USPTO issues patent number to Vermillion's biomarkers for detecting ovarian cancer

Nov 12 2009

Vermillion, Inc. (OTC: VRMLQ.PK), a molecular diagnostics company, today announced that the U.S. Patent Office (USPTO) has issued patent number 7,605,003 titled "Use of biomarkers for detecting ovarian cancer" to the Company for the discovery of biomarkers for ovarian cancer. The patent covers biomarker combinations for both the diagnosis and management of ovarian cancer and covers measurement of the markers by a variety of methods, including mass spectrometry and immunoassay approaches.

"Vermillion has been creating a comprehensive patent portfolio to protect our ovarian cancer testing franchise. The issuance of this patent supports our overall intellectual property strategy and we continue to pursue additional patent applications in support of our diagnostic programs," said Gail S. Page, Vermillion Executive Chairperson.